Demographic and clinical characterization of patients with Cerebral Palsy undergoing an infiltration procedure with Botulinum Toxin Type A at the Teleton Santiago Institute during 2017. A pharmaco-epidemiological study

Abstract

Background: Botulinum Toxin Type A (TBA) is a biological product used as a rehabilitation treatment in patients with cerebral palsy (CP), administered through an infiltration procedure. The objective is to characterize demographically and clinically the population of patients diagnosed with CP who undergo an infil­tration procedure at the Teleton Santiago Institute (TSI). Materials or patients and Methods: A cross-sectional pharmaco-epidemiological study was carried out with the records of patients infiltrated with two types of BTA (Botox® or Dys­port®) in the TSI, between the months of March to December of 2017. Results: 351 clinical records corresponding to the target population were reviewed, where 38.75% corresponded to females (n = 136) and 61.25% to males (n = 215), with an average age of 8,3 (SD 4,4) years old and a predominant clinical diagnosis of PC Spastic (80,63%, n = 283). OnabotulinumtoxinA (Botox®) and Abobotuli- numtoxinA (Dysport®) were administered in 90,60% (n = 318) and 9,40% (n = 33) of the population respectively. The most used dose interval of Botox® was 115-220 U and Dysport® was 400 - 620 U. The most used infiltration technique was electrostimulation (EE) (52,14%; n = 183) and the muscles with more infiltration frequency were gastrocnemius (23,05%), gracilis (10.79%), hamstrings (10.06%), adductor longus (9.56%) and soleus (6.07%). Conclusions: Demographically and clinically characterizing the population subjected to infiltration procedure with TBA, allows to visualize the current situation of use of the infiltration as a coadjuvant of the rehabilitation in the patient with PC and to project continuous improvements in the most efficient and effective use of the drug.